The importance of Targacept Inc.’s research breakthrough to its top partner became a little clearer yesterday.
AstraZeneca PLC said it received approval from the Food and Drug Administration to use its Seroquel XR drug as an add-on treatment for major depressive disorder.
Seroquel XR is an extended-release version of schizophrenia medication Seroquel, a top seller for the company. That drug already is approved for bipolar disorder and schizophrenia. Story continues here ➤